Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05802069 · ClinicalTrials.gov registry record
MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)
A clinical trial of Cancer, sponsored by Sameem M. Abedin, MD.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT05802069: Recruiting study of Cancer, sponsored by Sameem M. Abedin, MD.
NCT05802069 is a study of Cancer that is actively recruiting participants, run by Sameem M. Abedin, MD. The registered enrollment target is 10,000 participants, above the 3,475-participant average among 615 other Cancer trials with a reported enrollment target (188% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05802069, a study of Cancer, is actively recruiting participants, sponsored by Sameem M. Abedin, MD.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is an observational trial for patients undergoing cancer-related interventions and therapy at Medical College of Wisconsin Cancer Center. Projects under this protocol will use patient data that will be collected both retrospectively and prospectively. It will also enable prospective sample collection for specific cancer-related studies.
Primary Outcome
Precision therapies are targeted against specific genomic mutations.
Conditions Studied
Study Locations (1)
Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2027-12 |
What NCT05802069 shows while recruiting
NCT05802069 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,475-participant average among 615 other Cancer trials with a reported enrollment target (188% higher).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05802069 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05802069 about?
NCT05802069 is a clinical study titled "MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)". The study is an observational trial for patients undergoing cancer-related interventions and therapy at Medical College of Wisconsin Cancer Center. Projects under this protocol will use patient data that will be collected both retrospectively and prospectively. It will also enable prospective sample...
What is the current status of trial NCT05802069?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2022-12-19. Estimated completion is 2027-12.
What conditions does trial NCT05802069 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT05802069?
This trial is sponsored by Sameem M. Abedin, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05802069 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05802069's enrollment target sits among peer trials
10,000 23rd of 615 higher than 584 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
- NCT01000883 · 10,000 participants
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI